SCHEMBL18274731

SCHEMBL18274731

NCCOC(=O)C(N)Cc1c[nH]c2ccccc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.67
▸ MEN1 O00255 2/20 0.67
▸ LMNA P02545 2/20 0.67
▸ KMT2A Q03164 2/20 0.67
▸ KDM4E B2RXH2 2/20 0.67
▸ MPO P05164 2/20 0.67
▸ TSHR P16473 1/20 0.67
▸ BLM P54132 1/20 0.67
▸ PMP22 Q01453 1/20 0.67
▸ HIF1A Q16665 1/20 0.67
▸ TACR1 P25103 2/20 0.64
▸ HTR2A P28223 3/20 0.54
▸ HTR1D P28221 2/20 0.54
▸ HTR1B P28222 2/20 0.54
▸ HTR2C P28335 2/20 0.54
▸ HTR7 P34969 2/20 0.54
▸ HTR6 P50406 2/20 0.54
▸ ADRB1 P08588 1/20 0.54
▸ HTR1A P08908 1/20 0.54
▸ ADRA2A P08913 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18274732 1.00 MAPT (0.67) MAPTMEN1LMNAKMT2AKDM4E
SCHEMBL5925173 0.90 MAPT (0.67) MAPTMEN1LMNAKMT2AKDM4E
SCHEMBL5925171 0.90 MAPT (0.67) MAPTMEN1LMNAKMT2AKDM4E
SCHEMBL10586676 0.88 TACR1 (0.66) MAPTMEN1LMNAKMT2AKDM4E
SCHEMBL27568427 0.88 TACR1 (0.66) MAPTMEN1LMNAKMT2AKDM4E
SCHEMBL23723484 0.88 MAPT (0.76) MAPTMEN1LMNAKMT2AKDM4E
SCHEMBL29472033 0.88 MAPT (0.76) MAPTMEN1LMNAKMT2AKDM4E
SCHEMBL21012639 0.87 CYP1A2 (0.55) MAPTMEN1LMNAKMT2AKDM4E
Hydrochloric Acid SCHEMBL10587119 0.87 TACR1 (0.65) MAPTMEN1LMNAKMT2AKDM4E
Hydrochloric Acid SCHEMBL28036505 0.87 TACR1 (0.65) MAPTMEN1LMNAKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10919840-B2 Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials SEIKAGAKU CORPORATION (JP) 2021-02-16 — — US disclosed
EP-3101064-B1 DIAMINE CROSSLINKING AGENT, ACIDIC POLYSACCHARIDE CROSSLINKED BODY, AND MEDICAL MATERIAL SEIKAGAKU KOGYO CO LTD (JP) 2020-07-15 — — EP disclosed
US-20190345312-A1 DIAMINE CROSSLINKING AGENTS, CROSSLINKED ACIDIC POLYSACCHARIDES AND MEDICAL MATERIALS SEIKAGAKU CORPORATION (JP) 2019-11-14 — — US disclosed
US-10294195-B2 Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials SEIKAGAKU CORPORATION (JP) 2019-05-21 — — US disclosed
US-20170001948-A1 DIAMINE CROSSLINKING AGENTS, CROSSLINKED ACIDIC POLYSACCHARIDES AND MEDICAL MATERIALS SEIKAGAKU CORPORATION (JP) 2017-01-05 — — US disclosed
EP-3101064-A1 DIAMINE CROSSLINKING AGENT, ACIDIC POLYSACCHARIDE CROSSLINKED BODY, AND MEDICAL MATERIAL Seikagaku Corporation (JP) 2016-12-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10294195-B2 Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials SAT1, ACMSD, ADM2 MAPT 993/4885MEN1 2165/4885LMNA 3691/4885
US-20170001948-A1 DIAMINE CROSSLINKING AGENTS, CROSSLINKED ACIDIC POLYSACCHARIDES AND MEDICAL MATERIALS SAT1, ACMSD, ADM2 MAPT 993/4885MEN1 2165/4885LMNA 3691/4885
US-10919840-B2 Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials SAT1, ACMSD, ADM2 MAPT 993/4885MEN1 2165/4885LMNA 3691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback